In a recent announcement from SOPHIA ANTIPOLIS, France, Median Technologies has revealed that their eyonis® LCS, an AI-powered Software as a Medical Device for early cancer diagnosis, has received CE marking as a Class IIb medical device. The company, known for its innovative solutions and services in oncology, is recognized for providing AI-based image analyses and central imaging services to oncology drug developers. Median Technologies, with the stock symbol FR0011049824, ALMDT, is setting new standards with their cutting-edge technology aimed at transforming cancer diagnostics. This achievement marks a significant milestone for the company and reinforces its position as a global leader in the AI healthcare sector.